Azo mediators and methods of use thereof
US-9840729-B2 · Dec 12, 2017 · US
US9862693B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9862693-B2 |
| Application number | US-201414566055-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 10, 2014 |
| Priority date | Jun 11, 2012 |
| Publication date | Jan 9, 2018 |
| Grant date | Jan 9, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Presented herein inter alia are novel compounds and methods of using the same for the treatment of cancers.
Opening claim text (preview).
What is claimed is: 1. A compound having the formula: wherein; L 1 and L 2 are independently a bond or —NH—C(NH)—; R 1 is —NR 1A R 1B , wherein R 1A and R 1B are independently substituted or unsubstituted alkyl and are joined together to form a substituted or unsubstituted pyrrolidinyl, or an unsubstituted piperidinyl; R 2 is —NR 2A R 2B , wherein R 2A and R 2B are independently substituted or unsubstituted alkyl and are joined together to form a substituted or unsubstituted pyrrolidinyl; and R 3 is hydrogen or unsubstituted C 1 -C 5 alkyl. 2. The compound of claim 1 , wherein L 1 and L 2 are bonds and R 3 is hydrogen. 3. The compound of claim 2 , wherein R 1A and R 1B are joined together to form an unsubstituted piperidinyl. 4. The compound of claim 1 , wherein said compound has the formula: 5. The compound of claim 4 , wherein R 3 is hydrogen. 6. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound having formula: wherein; L 1 and L 2 are independently a bond or —NH—C(NH)—; R 1 is —NR 1A R 1B , wherein R 1A and R 1B are independently substituted or unsubstituted alkyl and are joined together to form a substituted or unsubstituted pyrrolidinyl, or an unsubstituted piperidinyl; R 2 is —NR 2A R 2B , wherein R 2A and R 2B are independently substituted or unsubstituted alkyl and are joined together to form a substituted or unsubstituted pyrrolidinyl; and R 3 is hydrogen or unsubstituted C 1 -C 5 alkyl. 7. The pharmaceutical composition of claim 4 , wherein said compound has the formula:
linked by a chain containing hetero atoms as chain links · CPC title
Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2) · CPC title
Antineoplastic agents · CPC title
Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title
X and Y being nitrogen atoms, i.e. biguanides · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.